Biogen (BIIB) Cash from Financing Activities (2009 - 2026)

Biogen has reported Cash from Financing Activities for 18 years, with the latest figure at $1.3 billion in Q2 2026.

• On a quarterly basis, Cash from Financing Activities rose 11176.92% year-over-year to $1.3 billion in Q2 2026; TTM through Jun 2026 was $985.0 million, a 3049.1% increase from a year earlier, with the FY2025 full-year figure at -$301.9 million, up 55.83% from the prior year.
• Cash from Financing Activities was $1.3 billion for Q2 2026 at Biogen, up from -$43.8 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $1.3 billion in Q2 2026, with the low at -$1.3 billion in Q3 2022.
• Average Cash from Financing Activities over 5 years is -$74.0 million, with a median of -$33.2 million recorded in 2023.
• The sharpest annual moves came in 2023 and 2026: Cash from Financing Activities slumped 8631.08% in 2023, then soared 11176.92% in 2026.
• Over 5 years, Cash from Financing Activities stood at -$7.4 million in 2022, then plunged by 8631.08% to -$646.1 million in 2023, then jumped by 101.22% to $7.9 million in 2024, then plunged by 1834.18% to -$137.0 million in 2025, then surged by 1045.99% to $1.3 billion in 2026.
• The last three Cash from Financing Activities figures came in at $1.3 billion (Q2 2026), -$43.8 million (Q1 2026), and -$137.0 million (Q4 2025), per Business Quant data.